SENS Chief Medical Officer Francine Kaufman Sells $29K of Stock

On June 15, 2026, Francine Kaufman, the Chief Medical Officer of SENS, sold 4,010 shares of the company. The shares were sold at an average price of $7.18, resulting in a total transaction value of $28,791.80. This move comes as part of a series of insider transactions at the company.

Insider Buying and Selling at Senseonics Holdings, Inc.

Several insiders at SENS executed sales on the same day as Kaufman. Kenneth Horton, the General Counsel & Corporate Development Advisor, sold 9,545 shares, while Brian Hansen, the Chief Commercial Officer, sold 5,420 shares. Mukul Jain, the Chief Operating Officer, and Frederick Sullivan, the Chief Financial Officer, sold 16,194 and 5,397 shares, respectively. Timothy Goodnow, the President and CEO, also sold 32,598 shares. All transactions were executed at the same price of $7.18 per share.

Other Institutional Activity in SENS

Institutional investors have also been active in SENS. SESSA Capital IM, L.P. significantly increased its position by adding 1,766,093 shares, bringing its total to 1,766,093 shares valued at approximately $11.76 million. Vanguard Capital Management LLC followed suit by acquiring 1,617,197 shares, now holding the same amount worth about $10.77 million. Meanwhile, BlackRock, Inc. reduced its stake by 26,035 shares, leaving it with 568,729 shares valued at $3.79 million. Millennium Management LLC and Masters Capital Management LLC also showed increased confidence, adding 459,083 and 250,002 shares, respectively.

Senseonics Holdings, Inc. Stock Down 30.2%

Shares of SENS recently traded at $6.69. The stock has seen varied institutional interest, with some funds increasing their stakes significantly. The company's current market environment reflects diverse investor strategies.

Analysts Set New Price Targets

Analyst activity has remained robust around SENS. On May 12, 2026, HC Wainwright & Co. maintained a 'buy' rating with a price target of $14.00. Stifel, on May 11, 2026, also maintained its 'hold' rating, setting a price target of $8.00. These ratings suggest a range of expectations from analysts.

Bottom Line

Francine Kaufman's recent sale of SENS shares is part of a broader trend of insider transactions at the company. Institutional investors have shown mixed actions, with some increasing their positions significantly. Analyst ratings remain varied, indicating differing outlooks on the company's future performance. As always, it's important to remember that insider transactions can be for various reasons and do not necessarily indicate a change in company outlook.